K241787Substantially Equivalent
CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood Glucose Monitoring System
Medrad, Inc., Parsippany NJ / Traditional, Substantially Equivalent
K241787 is the FDA 510(k) clearance record for CONTOUR® PLUS BLUE Blood Glucose Monitoring System; CONTOUR® NEXT GEN Blood Glucose Monitoring System, a class II device, cleared for Ascensia Diabetes Care U.S., Inc. on under FDA product code NBW (System, Test, Blood Glucose, Over The Counter). FDA records list 177 510(k) clearances for Medrad, Inc., from to . As of , FDA records show no recalls naming K241787.
Clearance record
- Decision date
- Received
- (67 days to decision)
- Product code
- NBW System, Test, Blood Glucose, Over The Counter
- Regulation
- 21 CFR 862.1345
- Device class
- Class II
- Review panel
- Clinical Chemistry
- Applicant
- Ascensia Diabetes Care U.S., Inc. 5 Wood Hollow Rd., Parsippany NJ
- 510(k) summary
- Summary PDF
- Third party review
- No
Clearances, product code NBW
Trailing 12 monthsShow the numbers
| Month | Clearances |
|---|---|
| November 2025 | 0 |
| December 2025 | 0 |
| January 2026 | 0 |
| February 2026 | 0 |
| March 2026 | 0 |
| April 2026 | 0 |
| May 2026 | 0 |
| June 2026 | 0 |
| July 2026 | 1 |
| August 2026 | 1 |
| September 2026 | 0 |
| October 2026 | 0 |
FIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
